Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance

被引:24
作者
Lei, Pan [1 ,2 ]
Wang, Wenzhou [1 ]
Sheldon, Marisela [3 ]
Sun, Yutong [4 ]
Yao, Fan [1 ,2 ,5 ,6 ,7 ]
Ma, Li [3 ,8 ]
机构
[1] Huazhong Agr Univ, Coll Biomed & Hlth, Hubei Hongshan Lab, Wuhan 430070, Peoples R China
[2] Hubei Univ Med, Taihe Hosp, Sch Basic Med Sci, Hubei Key Lab Embryon Stem Cell Res, Shiyan 442000, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[5] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan 430070, Peoples R China
[6] Huazhong Agr Univ, Shenzhen Inst Nutr & Hlth, Shenzhen 518000, Peoples R China
[7] Chinese Acad Agr Sci, Agr Genom Inst Shenzhen, Shenzhen Branch, Guangdong Lab Lingnan Modern Agr,Genome Anal Lab,M, Shenzhen 518000, Peoples R China
[8] Univ Texas MD Anderson Canc Ctr UTHealth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
breast cancer; glucose metabolism; metastasis; drug resistance; Warburg effect; reverse Warburg effect; tumor microenvironment; metabolic inhibitor; POSITRON-EMISSION-TOMOGRAPHY; PYRUVATE-KINASE; AEROBIC GLYCOLYSIS; PHOSPHOGLYCERATE DEHYDROGENASE; TUMOR MICROENVIRONMENT; MOLECULAR PORTRAITS; SERINE SYNTHESIS; CELL-MIGRATION; HEXOKINASE; PHASE-I;
D O I
10.3390/cancers15133390
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new targets for breast cancer treatment. By understanding what enzymes and pathways are involved, researchers may be able to develop drugs that specifically target these pathways, ultimately leading to more effective and less toxic treatments for breast cancer in the future. The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment.
引用
收藏
页数:18
相关论文
共 146 条
[1]   Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy [J].
Abdel-Wahab, Ali F. ;
Mahmoud, Waheed ;
Al-Harizy, Randa M. .
PHARMACOLOGICAL RESEARCH, 2019, 150
[2]   EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET [J].
ADLER, LP ;
CROWE, JP ;
ALKAISI, NK ;
SUNSHINE, JL .
RADIOLOGY, 1993, 187 (03) :743-750
[3]   Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer [J].
Aggelis, Vassilis ;
Johnston, Stephen R. D. .
DRUGS, 2019, 79 (17) :1849-1866
[4]   Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial [J].
Amadori, D ;
Frassineti, GL ;
De Matteis, A ;
Mustacchi, G ;
Santoro, A ;
Cariello, S ;
Ferrari, M ;
Nascimben, O ;
Nanni, O ;
Lombardi, A ;
Scarpi, E ;
Zoli, W .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) :209-217
[5]   Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments [J].
Angelin, Alessia ;
Gil-de-Gomez, Luis ;
Dahiya, Satinder ;
Jiao, Jing ;
Guo, Lili ;
Levine, Matthew H. ;
Wang, Zhonglin ;
Quinn, William J., III ;
Kopinski, Piotr K. ;
Wang, Liqing ;
Akimova, Tatiana ;
Liu, Yujie ;
Bhatti, Tricia R. ;
Han, Rongxiang ;
Laskin, Benjamin L. ;
Baur, Joseph A. ;
Blair, Ian A. ;
Wallace, Douglas C. ;
Hancock, Wayne W. ;
Beier, Ulf H. .
CELL METABOLISM, 2017, 25 (06) :1282-+
[6]   Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose:: Use and limitations [J].
Avril, N ;
Rosé, CA ;
Schelling, M ;
Dose, J ;
Kuhn, W ;
Bense, S ;
Weber, W ;
Ziegler, S ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3495-3502
[7]   Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Bense, S ;
Ziegler, S ;
Laubenbacher, C ;
Romer, W ;
Pache, H ;
Herz, M ;
Allgayer, B ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1848-1857
[8]  
Avril N, 2001, J NUCL MED, V42, P9
[9]  
Avril Norbert, 1999, Clin Positron Imaging, V2, P261, DOI 10.1016/S1095-0397(99)00032-1
[10]   Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy [J].
Bader, Jackie E. ;
Voss, Kelsey ;
Rathmell, Jeffrey C. .
MOLECULAR CELL, 2020, 78 (06) :1019-1033